STAAR Surgical Co. (NASDAQ:STAA) jumped 20.07% to $25.07 in after-hours trading on Wednesday after reporting preliminary first-quarter 2026 net sales of more than $90 million, up from $42.6 million in the same period last year.
China, Americas Drive Growth
Interim Co-CEO and CFO Deborah Andrews said China, the company’s largest market, fueled most of the increase, with double-digit growth in the Americas. She added that higher sales, paired with a streamlined cost structure, should boost adjusted EBITDA.
“These results deliver on two of the three core objectives outlined in our Shareholder Letter earlier this year—Revenue Growth and Profit Expansion—and though early in the year, are indicators of the overall good health of our business,” said Andrews.
Global Challenges Persist
The California-based medical device company …
